Astellas

Patients

Patient engagement processes: the pharmaphorum podcast

This episode of the pharmaphorum podcast is the second in a limited series focused on patient engagement that’s being led by clinician, consultant and patient advocate, Mark Duman.

Patients

new-drug discovery, development, and delivery

From patient engagement to patient centricity

Words matter. In the pharma industry, “patient engagement” and “patient centricity” might seem like interchangeable bits of corporate jargon.

News

Trial closes gap between Bayer's Nubeqa and rivals in prosta...

Bayer's Nubeqa is making headway as a treatment for castration-resistant prostate cancer (CRPC), but could be on track to expand its eligible patient population thanks to new phase 3 data.<

News

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

Dyno attracts $1.6bn gene therapy deal with Astellas

Astellas has signed another bolt-on deal to build its gene therapy pipeline, agreeing a deal with Dyno Therapeutics to tap into its adeno-associated virus (AAV) vector platform for deliveri

Patients

Time for a new model in patient access

Mig Sleeper, vice president, Global Pricing for Astellas Pharma Europe, explains why we must rethink how value is defined as we enter a new technological era for medicines.

News

Astellas reports fourth death in halted gene therapy trial

There has been a fourth patient fatality in Astellas' clinical trial of its AT132 gene therapy for the rare disease X-linked myotubular myopathy (XLMTM), which has been halted twice due to

Patient engagement processes: the pharmaphorum podcast

From patient engagement to patient centricity

Trial closes gap between Bayer's Nubeqa and rivals in prosta...

Dyno attracts $1.6bn gene therapy deal with Astellas

Time for a new model in patient access

Astellas reports fourth death in halted gene therapy trial

Praxis soars on rare childhood epilepsy trial data

How to meet your physicians where they are online

Astellas

Editor's Picks